Free Newsletter
Novartis CEO's statin? Pfizer's Lipitor
Free newsletter via e-mail
Tools
What's a pharma CEO with high cholesterol to do? Take his company's statin, of course. But Novartis chief Daniel Vasella (photo) eschews Lescol in favor of... Pfizer's Lipitor. Vasella tried Lescol. Twice. But side effects pushed him off the drug and onto Lipitor.
As the Wall Street Journal's Health Blog notes, Vasella's experience is just one of the many times Lescol has lost out. Viewed as less potent than other statins, Lescol totes up global sales of less than $1 billion, compared with $10 billion for Lipitor. And both now are losing out to Zocor imitators.
- check out the item from the Health Blog
Related Articles:
Sleep study could boost some statins. Report
Switching to generic statins not so healthy. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: